Cardio Diagnostics Pioneers AI-Driven Blood Test for Heart Disease

Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and multi-omic biomarkers to deliver actionable insights from a simple blood sample, enabling more informed and timely care cardiac care decisions. The scale and impact of cardiovascular disease underscore why innovation in this area is so critical. According to the Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States, responsible for approximately one in every three deaths. Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression. By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing.

Cardio Diagnostics Holdings, listed on NASDAQ under the ticker CDIO, is at the forefront of integrating AI with multi-omic biomarkers to transform cardiovascular disease detection and management. The company's approach involves a simple blood test that can provide comprehensive insights into a patient's cardiovascular health, potentially identifying risks earlier than traditional methods. This innovation is particularly significant given the high mortality rates associated with heart disease, which remains the leading cause of death in the US. The ability to detect and manage cardiovascular disease more effectively could lead to better patient outcomes and reduced healthcare costs.

The news release was distributed by MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. For more information, visit MissionIR.